Epinephrine Global Market Report 2024

“Epinephrine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epinephrine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epinephrine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The epinephrine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Prefilled Syringe; Auto-injector; Ampoules and Vials
• 2) By Application: Anaphylaxis; Cardiac Arrest; Superficial Bleeding; Respiratory Disorders; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: ALK-Abello A/S; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan NV; Amneal Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Epinephrine, commonly known as adrenaline, serves as both a hormone and neurotransmitter. It is primarily used for the treatment of life-threatening allergic reactions triggered by various factors such as foods, medicines, latex, insect bites or stings, and other allergens. Epinephrine injections are administered as part of emergency medical treatment for such reactions.

The main types of epinephrine formulations include prefilled syringes, auto-injectors, ampoules, and vials. Prefilled syringes are disposable syringes pre-loaded with the medication, designed for self-administration in a single, preloaded dose. This eliminates the need to handle adrenaline ampoules and complete the drawing-up procedure, enhancing convenience and safety. Epinephrine is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used for a range of applications, including the treatment of anaphylaxis (severe allergic reactions), cardiac arrest, superficial bleeding, respiratory disorders, and other emergency situations where the effects of adrenaline are critical for immediate medical intervention.

The epinephrine market research report is one of a series of new reports from The Business Research Company that provides epinephrine market statistics, including the epinephrine industry's global market size, regional shares, competitors with an epinephrine market share, detailed epinephrine market segments, market trends, and opportunities, and any further data you may need to thrive in the epinephrine industry. This epinephrine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epinephrine market size has grown rapidly in recent years. It will grow from $2.44 billion in 2023 to $2.69 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth observed in the historic period in the field of epinephrine can be attributed to several factors. These include the incidence of anaphylaxis, which is a severe and potentially life-threatening allergic reaction, leading to an increased demand for epinephrine as a crucial intervention. Additionally, the presence of a regulatory framework governing the use and availability of epinephrine, the rising prevalence of allergies, efforts in patient education regarding the importance of epinephrine in managing severe allergic reactions, and improved accessibility to epinephrine products have all contributed to the growth during the historic period. These factors collectively influenced the adoption and utilization of epinephrine for emergency medical situations.

The epinephrine market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period in the field of epinephrine can be attributed to several factors. These include the continued rise in allergy rates, initiatives aimed at expanding access to epinephrine, awareness campaigns highlighting the importance of emergency treatment for severe allergic reactions, the exploration of emerging markets, and the development of customized epinephrine delivery systems. Major trends expected in this period include the integration of smart devices in the administration of epinephrine, enhanced education and awareness programs to ensure proper use, the global expansion of access to epinephrine products, regulatory emphasis on product safety standards, and collaborative efforts for research and development in the field. These trends collectively contribute to the evolving landscape of epinephrine use and accessibility in the forecast period.

The escalation in the prevalence of chronic respiratory diseases is expected to drive the growth of the epinephrine market in the foreseeable future. Chronic respiratory diseases encompass a range of medical conditions affecting the lungs and airways, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis. These conditions are increasingly prevalent due to various factors such as air pollution and harmful environmental or occupational exposures. Epinephrine, a critical medication used to treat severe asthma attacks and anaphylactic reactions, plays a vital role in managing respiratory distress and life-threatening complications. Globally, chronic respiratory diseases account for a significant portion of non-communicable disease-related deaths, totaling 4.1 million fatalities annually, according to the World Health Organization's September 2023 report. As the incidence of chronic respiratory diseases rises, the demand for epinephrine is expected to grow correspondingly.

The upsurge in healthcare spending is anticipated to be a driving force behind the expansion of the epinephrine market in the coming years. Healthcare expenditure constitutes the total financial investment in healthcare-related goods and services within a specific healthcare system or economy. Increased healthcare expenditure supports the stocking of epinephrine in healthcare facilities such as hospitals, clinics, and emergency medical services. This contributes to wider accessibility of epinephrine auto-injectors or other delivery methods, ensuring availability for individuals with severe allergies. For instance, in November 2022, the Canadian Institute for Health Information reported an increase in healthcare expenditure to $331 billion, a rise of 0.8% compared to the preceding year. This surge, from 7.6% in 2021, underlines the crucial role of escalating healthcare spending in driving the growth of the epinephrine market.

Product innovation stands out as a pivotal trend gaining traction in the epinephrine market. Leading companies in the sector are actively engaged in developing advanced products, including auto-injectors or enhanced delivery mechanisms, to enhance ease of use and fortify their market position. An example of this trend is Baxter International Inc.'s September 2021 launch of Premix Norepinephrine Bitartrate in 5% Dextrose Injection, following approval from the US Food and Drug Administration (FDA). This formulation of norepinephrine bitartrate offers a convenient dosage format in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) for adult patients experiencing severe, acute hypotension, aiding in raising blood pressure effectively.

Major companies in the epinephrine market are actively innovating their product lines, exemplified by the development of OX640, aiming to secure a competitive advantage. OX640 represents a breakthrough in the market, providing a needle-free, user-friendly, and efficient treatment solution for acute allergic reactions, notably anaphylaxis, catering to both community and healthcare settings. In August 2023, Orexo AB, a Sweden-based pharmaceutical company, announced the granting of the first US patent specifically dedicated to OX640 by the United States Patent and Trademark Office (USPTO). This patent signifies a pivotal milestone for Orexo, underscoring the distinctiveness and inventiveness of OX640, particularly its underlying amorphous drug delivery platform, amorphOX. The granted patent in the US not only validates the novelty of the product but also endorses the innovative drug delivery technology behind it.

In November 2021, Marathon Asset Management, LP, a US-based investment management company, completed the acquisition of Kaleo for $310 million. This strategic acquisition aligns with Kaleo's strategic vision of enhancing patient care for individuals at risk of anaphylaxis and other severe life-threatening conditions, leveraging Marathon's proficient management team with expertise in allergists' domain. Kaleo, a US-based pharmaceutical company, is dedicated to pioneering innovative healthcare products, including those related to epinephrine injections, and this acquisition is poised to strengthen its service offerings in the healthcare industry.

Major companies operating in the epinephrine market report are ALK-Abello A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Abbott Laboratories, Sanofi SA, Viatris Inc., Lincoln Medical Ltd., Kaleo Inc., Gland Pharma Limited, Adamis Pharmaceuticals Corporation, Harvest Pharmaceuticals Inc., Merit Pharmaceutical, Hospira, Inc., Antares Pharma Inc., Bausch & Lomb Incorporated, Novartis AG, Grand Pharma (China) Co. Ltd., Impax Laboratories LLC, Sandoz International GmbH, Tianjin Jinyao Group Co. Ltd., GlaxoSmithKline plc, Amphastar Pharmaceuticals Inc., Par Sterile Products LLC, Amedra Pharmaceuticals LLC, Crossject SA, Halozyme Therapeutics Inc .

North America was the largest region in the epinephrine market in 2023. The regions covered in the epinephrine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the epinephrine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epinephrine market consists of sales of dl-Epinephrine and methyl epinephrine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.